A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions
Condition: Healthy
Intervention: Tramadol HCl
Intervention description: Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
Intervention MeSH terms: Tramadol
Phase: Phase 1
Study type: Interventional
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 26.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers
Keywords: Healthy volunteers

Summary:

      To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg
      film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated
      tablets, are bioequivalent.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and female subjects 18 to 55 years of age (inclusive).

          -  Body mass within 10% of the ideal mass in relation to height and age, according to the
             Body Mass Index (BMI).

          -  Body mass not less than 60 kg.

          -  Findings within the range of clinical acceptability in medical history and physical
             examination, and laboratory results within the "normal ranges" for the relevant
             laboratory tests (unless the investigator considered the deviation to be irrelevant
             for the purpose of the study).

          -  Normal electrocardiogram (ECG) and vital signs, or abnormalities which the
             investigator did not consider a disqualification for participation in the study.

          -  Willingness to undergo a pre-study physical examination and pre- and post-study
             laboratory investigations.

          -  Ability to comprehend and willingness to sign both statements of informed consent (for
             screening and phase-related procedures).

          -  Non-smoker or past smoker who stopped smoking at least 3 months before entering the
             study.

          -  For females, the following conditions were to be met:

               -  had been postmenopausal for at least 2 years, or

               -  had been surgically sterilized, or

               -  was of childbearing potential, and all of the following conditions were met:

                    -  had a normal menstrual flow within 1 month before study entry, and

                    -  had negative serum pregnancy test at screening. If this test was positive,
                       the subject was to have been excluded from the study before receiving study
                       medication. In the rare circumstance that a pregnancy was discovered after
                       the subjects received study drug, then every attempt must be made to follow
                       such subjects to term, and

                    -  must agree to use an accepted method of contraception (i.e., spermicide and
                       barrier methods or spermicide and Intrauterine Device (IUD)). The subject
                       had to agree to continue with the same method throughout the study. Hormonal
                       contraceptives will not be allowed.

        Exclusion Criteria:

          -  Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional
             or intellectual problems likely to limit the validity of consent to participate in the
             study or limit the ability to comply with protocol requirements.

          -  History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular
             exposure to other substances of abuse.

          -  Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the
             first administration of study medication except if this would not have affected the
             outcome of the study in the opinion of the clinical investigator. Use of hormonal
             contraceptive agents by females were not allowed.

          -  Participation in another study with an experimental drug within 8 weeks before the
             first administration of study medication.

          -  Treatment within the previous 3 months with any drug with a well-defined potential for
             adversely affecting a major organ or system with evidence to this effect.

          -  A major illness during the 3 months before commencement of the screening period.

          -  History of hypersensitivity to the study drug or any related drugs.

          -  History of bronchial asthma.

          -  History of epilepsy.

          -  Relevant history or laboratory or clinical findings indicative of acute or chronic
             disease, likely to influence study outcome.

          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the
             first administration of study medication.

          -  Diagnosis of hypotension made during the screening period.

          -  Diagnosis of hypertension made during the screening period or current diagnosis of
             hypertension.

          -  Resting pulse of >100 beats per minute or <45 beats per minute during the screening
             period, either supine or standing.

          -  Positive testing for hepatitis B antigen.

          -  Significant liver disease, defined as active hepatitis or elevated liver enzymes
             (e.g., AST (aspartate aminotransferase), Alanine transaminase (ALT)) >2 times the
             upper boundary of the normal range.

          -  Positive urine screen for drugs of abuse.

          -  Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step
             Cotinine (COT) Tests).

          -  A serum pregnancy test (beta-hCG) either positive or not performed or lactation.

          -  History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months
             prior to study start.

          -  Participation in a tramadol study within the previous 12 months.